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ABSTRACT
The transcription factor NF-B has attracted widespread attention among re-
searchers in many fields based on the following: its unusual and rapid regulation,
the wide range of genes that it controls, its central role in immunological pro-
cesses, the complexity of its subunits, and its apparent involvement in several
diseases. A primary level of control for NF-B is through interactions with an
inhibitor protein called IB. Recent evidence confirms the existence of multiple
forms of IB that appear to regulate NF-B by distinct mechanisms. NF-B can
be activated by exposure of cells to LPS or inflammatory cytokines such as TNF or
IL-1, viral infection or expression of certain viral gene products, UV irradiation,
B or T cell activation, and by other physiological and nonphysiological stim-
uli. Activation of NF-B to move into the nucleus is controlled by the targeted
phosphorylation and subsequent degradation of IB. Exciting new research has
elaborated several important and unexpected findings that explain mechanisms
involved in the activation of NF-B. In the nucleus, NF-B dimers bind to target
DNA elements and activate transcription of genes encoding proteins involved
with immune or inflammation responses and with cell growth control. Recent
data provide evidence that NF-B is constitutively active in several cell types,
potentially playing unexpected roles in regulation of gene expression. In addi-
tion to advances in describing the mechanisms of NF-B activation, excitement
in NF-B research has been generated by the first report of a crystal structure for
one form of NF-B, the first gene knockout studies for different forms of NF-B
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and of IB, and the implications for therapies of diseases thought to involve the
inappropriate activation of NF-B.
1. INTRODUCTION
Ten years ago Sen & Baltimore (1) first described NF-B as a B cell nuclear
factor that bound a site in the immunoglobulin  enhancer. In the same year,
these researchers also showed (2) that NF-B could be activated in other cells
by exposure to stimuli such as phorbol esters, and that this activation was
independent of protein synthesis. In the next few years, functional NF-B
binding sites were found in the promoters of many genes, most of which were
not B cell specific. These promoter/enhancers included IL-2, IL-6, GM-CSF,
ICAM-1, and class I MHC. Typically, NF-B binding sites serve as inducible
transcriptional regulatory elements that respond to immunological stimuli such
as TNF, IL-1, LPS, or T cell activators. However, the range of inducers is
not limited to these mediators of immune function; other stimuli such as UV
irradation, growth factors, and viral infection also activate NF-B. The basis for
the latent nature of NF-B and for its inducibility is the association of NF-B
with a cytoplasmic inhibitory protein called IB (3). The release from IB
allows for the extraordinarily rapid appearance of NF-B in the nucleus. Thus,
certain genes regulated by NF-B can be transcriptionally activated within
minutes following exposure to the relevant inducer.
Ten years after its discovery, the NF-B and IB field remains a lively
arena for research. Five members of the mammalian NF-B/Rel proteins have
been identified that are characterized by the Rel homology domain (RHD), an
N-terminal region of approximately 300 amino acids. These proteins are mem-
bers of an evolutionarily conserved family of proteins, some of which regulate
body pattern formation and immune function in insects. Consistent with a
complex system for regulatory control, there are multiple forms of IB pro-
teins characterized by several copies of the so-called ankyrin repeat. Recent
research has elaborated several of the critical aspects of signaling that medi-
ate NF-B translocation in response to inducer. Gene knockout studies firmly
establish a role for NF-B in immune function and eliminate any models that
claim simple redundancy for the functions of the different NF-B/Rel pro-
teins. Regulation of NF-B by the network of regulatory cytokines and other
immune function modulators is now well established and is growing in com-
plexity. Additionally, the gene deletion studies as well as other approaches
provide support for a role of the NF-B proteins in functions beyond immunity
and inflammatory responses, including roles in liver development and in several
disease processes.
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Two recent Annual Reviews chapters (4, 5) have covered NF-B in great
detail through much of 1993. These and other reviews (6–12) offer a thorough
background on NF-B. The aim of this review is to provide coverage of some
of the significant advances in NF-B over the last two years. Many reports
involving NF-B have appeared during this time; due to space limitations, it is
impossible for this review to cover all of these important results. In addition,
reviews reference previous work where appropriate.
2. THE NF-B/REL AND IB PROTEINS
Presently, five members of the mammalian NF-B/Rel family have been cloned
and characterized. These are c-Rel, NF-B1 (p50/p105), NF-B2 (p52/p100),
RelA (p65), and RelB (4–12). The Rel homology domain (RHD; see Figure 1)
found in each of these proteins functions in DNA binding, dimerization, and
interactions with IB forms. Two of the proteins, NF-B1 (p105) and NF-B2
(p100), contain multiple copies of the so-called ankyrin repeat at their C-termini.
Figure 1 The NF-B/Rel and IB families of proteins. The NF-B/Rel family is characterized
by the presence of the Rel homology domain. The IB proteins have multiple copies of the ankyrin
repeat. NF-B1 and NF-B2 are proteins that contain both the Rel homology domain and ankyrin
repeats. Dorsal, Dif, and Cactus are Drosophila proteins. See text for discussion.
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Processing of these proteins (see below) leads to the production of the p50
and p52 subunits. The p100 and p105 proteins serve regulatory functions in
the cell (see below) and should not be considered exclusively as precursor
forms. Furthermore, some evidence suggests that alternative splicing of the
p105 mRNA leads to the translation of additional forms of this protein (13).
2.1 NF-B Is a Dimer of Variable Subunits
Active, DNA-binding NF-B is a dimer. Classic NF-B (the dimer of p50 and
RelA) has been the most intensively studied, although many other homo- and
heterodimers have been described. Certain dimers apparently do not exist; for
example, RelB dimerizes only with p50 or p52 (14). Each of the various NF-B
dimers may exhibit distinct properties. For example, binding site preference
has been identified for certain dimers. Classic NF-B binds the sequence 50
GGGRNNYYCC 30, whereas the RelA/c-Rel dimer binds to a sequence (50
HGGARNYYCC 300; H indicates A, C or T; R is purine; Y is pyrimdine) (15).
Selective binding sites for RelA/c-Rel heterodimers are found in the promoters
of several inducible genes, including those encoding tissue factor and GM-CSF
(15); the RelA/c-Rel dimer is inducible by LPS or by cytokines. The ability of
different dimers to recognize slightly different DNA targets increases the ability
of NF-B subunits to differentially regulate gene expression. More examples
of biologically relevant targets for the different dimers and of possible roles
in gene-specific transcription are needed. Additional differences between the
NF-B dimers include cell type specificity, differential subcellular localization,
differential interactions with forms of IB, and differential activation (4, 5).
2.2 Dimers of NF-B Are Targeted by Monomers of IB
Initial characterization of cytoplasmic NF-B revealed that it was associated
with either of two forms of IB–IB or IB (4, 5). The cloning of IB
(16, 17) allowed progress to be made at several levels. First, it was established
that IB contains ankyrin repeats (Figure 1). Second, IB retains NF-B
in the cytoplasm through masking of the nuclear localization sequences (4, 5,
9). Third, the identification of IB as an ankyrin repeat containing protein
allowed for the prediction that the function of the homologous ankyrin repeats
in the precursors of the p50 subunit (NF-B1) and of the p52 subunit (NF-
B2) was as an intramolecular IB (see 4, 5). Thus precursors dimerize with
another member of the Rel family through the RHD, and the C-terminal ankyrin
repeat region functions to retain this dimer in the cytoplasm (also see discussion
below). Finally, IB exhibited homology with a protein encoded by the gene
bcl-3 found to be translocated in certain lymphomas (see 4, 5, and below).
Immunoprecipitation studies indicate that IB is associated predominantly
with c-Rel- and RelA-containing dimers. Studies indicate that certain non-Rel
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or RelA-containing dimers are likely not to be strongly regulated by IB. For
example, IB exhibits a lower affinity for RelB-p52 heterodimers than for
RelB-p50 dimers (18), and this likely contributes to constitutive nuclear levels
of the former factor. RelB complexes in lymphoid cells may have a lower affinity
for IB due either to a modification to RelB or to a cell-specific cofactor (19).
IB interaction with NF-B subunits occurs with residues in the Rel homology
domain, and presumed contacts in or around the nuclear localization sequence
(NLS) appear to play critical functional roles in inhibiting nuclear localization
of NF-B (4, 9). In addition, data indicate that a single IB targets the NF-B
dimer (20, 21).
IB can be divided into three structural domains: a 70-amino-acid N-ter-
minal region, a 205-amino-acid internal region that is composed of ankyrin
repeats, and a C-terminal 42-amino-acid region that contains a so-called PEST
region. Mutation and protease sensitivity studies indicate that deletion of the N-
terminal or C-terminal region does not inhibit the ability of IB to interact with
NF-B (20, 22). However, deletion of the C-terminus does block the ability
of IB to inhibit DNA binding of NF-B (20). Mutations within the ankyrin
repeat block interactions with NF-B (4, 5). The discussion below describes
important regulatory aspects of the N- and C-terminal regions of IB.
Other forms of IB include the precursors NF-B1 and NF-B2, IBγ (an
independent protein derived from a unique transcript from NF-B1) which
appears to be limited only to mouse B cells, and Bcl-3 (Figure 1; see 4, 5). The
recently cloned IB is discussed below. Precursor proteins can dimerize with
other NF-B subunits to form dimer molecules that cannot bind to DNA and
that cannot translocate into the nucleus (4, 5). NF-B2 precursor p100 or its
C-terminus can form a trimeric complex with a dimer of NF-B subunits (23,
24), suggesting a different mechanism whereby precursors function in an IB-
like role. Bcl-3 is nuclear in its localization and functions as a transcriptional
activator with the p50 or p52 homodimer. Thus the ability of Bcl-3 to interact
with these forms of NF-B results in transcriptional activation rather than an
inhibition of nuclear transport or an inhibition of DNA binding (4, 5). Consistent
with these results is the observation (25) that the NLS region of p50 is apparently
not contacted by Bcl-3, in contrast to the interactions between IB and NF-B
subunits.
2.3 IB Appears To Have Properties Distinct from IB
As stated above, purification of NF-B revealed that two forms of IB were as-
sociated with NF-B dimers. One form, IB, is described above and has been
intensively studied. Recently, the 46-kDa IB was purified to homogeneity,
and a cDNA clone was derived (26). Like IB, IB contains ankyrin re-
peats (Figure 1) and is associated with NF-B forms in the cytoplasm of various
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cells. Like IB, IB preferentially interacts with dimers that contain c-Rel
or RelA. mRNA for IB is widely expressed, with an especially high level
in the testis. Where IB is targeted by a signaling pathway initiated by TNF,
IL-1, LPS, and PMA, IB reportedly is targeted only by pathways initiated
by LPS or by IL-1 (at least in the 70Z/3 pre-B cell line and in the Jurkat T
cell line). Further discussion of IB follows in the section on signaling and
activation of NF-B.
2.4 IB-R and IBL: Functional IB Molecules?
A cDNA clone for an ankyrin repeat-containing protein with homology to
mammalian and invertebrate IB proteins was recently reported (27). This
protein, IB-R, is most similar to the Drosophila IB homolog Cactus (Figure 1
and see below) and is expressed in epithelial cell lines but not in fibroblasts. Two
forms of RNA are detected (the smaller RNA is not large enough to encode the
described protein), with the larger form expressed in heart and skeletal muscle
but not in brain, lung, liver, or kidney. The IB-R protein inhibits the DNA
binding activity of the p50/RelA dimer and the p50 homodimer but not that
of the RelA homodimer, suggesting a preferential interaction with the 50-kDa
NF-B1 subunit. A regulatory role for IB-R has not yet been identified.
Another cDNA clone encoding a protein (IBL) with homology to IB family
members has been reported (28). The protein contains two complete and one
partial ankyrin repeat and is encoded by a gene in the major histocompatibility
complex. No functional studies on this protein have been presented.
3. STRUCTURAL AND EVOLUTIONARY STUDIES
ON NF-B
3.1 Crystallography of NFB1 Bound to DNA
Two groups recently described the crystal structure of the 50-kDa NF-B1 ho-
modimer bound to a B site (29, 30). In contrast with the relatively small DNA
binding domains of many other transcription factors, the DNA binding domain
of NF-B1 encompasses large regions of the RHD. These studies reveal that
the RHD folds into two distinct domains similar to those in the immunoglobu-
lin superfamily. DNA contacts are made on the B site by both domains, and
the C-terminal regions of the RHD constitute the dimerization interface. The
overall structure is striking and butterfly-like (see Figure 2). The general relat-
edness of the RHD in each of the immediate NF-B family members strongly
suggests that a similar overall structure will constitute the DNA binding and
dimerizations domains of each family member. However, distinct sequence
elements within these domains likely determine different functional properties
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Figure 2 Structure of the Rel homology domain of the p50 NF-B1 homodimer and its target
DNA sequence (see 29, 30). The more N-terminal region of the RHD is shown toward the bottom,
and the more C-terminal dimerization region at the top. DNA contacts are made in both domains.
(Photograph from Dr. S. Harrison.)
A
nn
u.
 R
ev
. I
m
m
un
ol
. 1
99
6.
14
:6
49
-6
81
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
03
/2
0/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
       February 20, 1996 10:47 Annual Reviews BALDCHPT AR11-25
656 BALDWIN
of the different subunits (31). Consistent with previous deletion studies, it is
proposed that amino acids in and around the NLS will constitute a composite
surface for interaction with IB. Another important feature is that the minor
groove is exposed in the center of the B site, allowing for the interaction of
HMG-I(Y) with certain B sites [see discussion of HMG-I(Y) below].
3.2 NF-B/Rel Proteins Are Members of a Larger Family
The factor NF-AT is strongly implicated in the inducible transcription of the IL-
2 gene and other cytokine genes. Interestingly, many similarities exist between
the NF-B and the NF-AT family of proteins (see 32 and references therein).
Both groups are inducible by activation of T cells, utilizing cytoplasmic/nuclear
translocation as a control mechanism, and this activation is blocked by the im-
portant immunosuppressant cyclosporin A. Additionally, both NF-AT and NF-
B interact with members of the Fos/Jun family of proteins (32). Furthermore,
the core sequence of the NF-AT recognition site, GGAAAA, is very similar
to an NF-B half-site. The recent cloning of members of the NF-AT family
demonstrates the existence of a region of NF-AT similar to the Rel homology do-
main of NF-B (32; 33). Overall these observations indicate the existence of an
extended family of Rel-like proteins that serve critical roles in immune function.
An impressive structural and functional homology exists between the mam-
malian NF-B/Rel proteins and two proteins, Dorsal and Dif (see Figure 1),
from Drosophila. Dorsal is involved in critical developmental pathways deter-
mining the dorsal-ventral patterning of the embryo (see 34). Dif serves a pro-
tective function, regulating bacteriocidal genes in response to endotoxin (35).
These proteins are regulated by an ankyrin repeat containing protein known as
Cactus (Figure 1; 34, 36), which functions very similarly to mammalian IB in
controlling nuclear/cytoplasmic localization of Dorsal (37).
4. BIOLOGY OF NF-B
4.1 Expression and Nuclear/Cytoplasmic Status
of NF-B Forms
Although NF-B is generally considered to be cytoplasmic in most cell types
until stimulation with an inducer, growing evidence provides a more com-
plex view. First, many cell types appear to have moderate levels of the p50
(NF-B1) homodimer. A role for this factor in constitutive-type transcription
is unclear, but it may provide low levels of transcriptional activity or it may
serve as a transcriptional repressor (4, 5). Since the p50 dimer can be targeted
by Bcl-3, it may serve as a DNA-binding anchor for transcriptional activation
by this IB-related protein (5). A protein similar to or identical to c-Rel is
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nuclear during the S phase of the cell cycle (38). Evidence has been provided
that NF-B (other than the p50 homodimer) is nuclear in corneal keratinocytes
(39) and in vascular smooth muscles cells (40). Following is a discussion of
some other cells where constitutive activation of forms of NF-B may play
important functional roles.
4.1.1 B CELLS The one widely accepted example of constitutively active (i.e.
nuclear) NF-B is in B cells. B lymphocytes develop by regulating an or-
dered expression of immunoglobulin genes, and one role for NF-B in B
cells is in regulating the Ig gene (7). Pre-B cell lines do not exhibit active
NF-B unless stimulated with cytokines or LPS. However, pre-B cells expanded
from Whitlock-Witte bone marrow cultures by treatment with IL-7, and then
maintained with a stromal cell feeder layer, exhibited active NF-B and Ig
transcription (41). Recently several groups have shown that the constitutive
form of NF-B in mature B cell lines is largely the p50-c-Rel heterodimer (42,
43). The p50-RelA heterodimer is found at expected levels in the cytoplasm
but is not nuclear in these cells. The mechanism accounting for nuclear levels
of c-Rel-p50 is not fully clear but may be explained by significantly increased
instability of IB and by increased transcription of the c-Rel gene (43, 44).
The functional significance of the constitutive nuclear activation of the c-Rel-
p50 heterodimer, and the relative lack of p50-RelA, in mature B cell lines is
not clear. Both heterodimers appear to activate Igk gene expression effectively
(43). NF-B RelA is a potent activator of c-myc transcription, as compared
to c-Rel, and anti-IgM treatment of a B cell line resulted in increased forms
of NF-B in the nucleus, increased transcription of c-myc, and apoptosis (44).
Thus, activation of the p50-RelA heterodimer may be deleterious to normal
B cell function, resulting in upregulation of c-myc and apoptosis. Additional
evidence for an important role for NF-B in B cell biology comes from studies
on the B cell surface receptor CD40, which is a member of the TNF receptor
family. Engagement of the CD40 receptor activates NF-B in B cell lines (45,
46), leading to the transcription of a gene encoding a zinc finger protein, A20,
which inhibits apoptosis (45). CD40 signaling blocks spontaneous apoptosis of
B cells in germinal centers and may be important in selecting B cells undergoing
somatic mutation (see 46). The studies with anti-IgM utilized WEH1 231
cells, while the studies with CD40 utilized Louckes and BJAB cells. Thus,
NF-B may have both positive and negative effects on apoptosis in B cells.
Additionally, activation of Nf-B by engagement of CD40 is likely to play
other important roles in B cells.
4.1.2 THYMOCYTES Experiments utilizing freshly isolated thymocytes found
that several factors that bind to a B site are constitutively activated in these cells
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(47). These factors include p50 homodimers, the p50-RelA heterodimer, and
c-Rel. Disruption of the thymic microenvironment led to the loss of these
binding activities, which suggests that an interaction between lymphocytes
and stromal cells provides a stimulus for the activation of NF-B/Rel nuclear
proteins. Some evidence suggests that c-Rel plays a role in the transition from
CD4C/CD8C double positive cells to CD4C or CD8C single positive cells. Gene
knockout studies with p50 or c-Rel do not indicate a role for these subunits in
T cell development (see below) but do not rule out a role for RelA.
4.1.3 NEURONS Numerous reports analyze the status of B binding activities
and NF-B-like forms in the brain. A brain B binding protein, called BETA,
has been described (48). The BETA complex can be supershifted with antibod-
ies against a large zinc finger protein called MBP-2/AGIE BP-1 (49). Other
work has identified two B binding complexes, DBF 1 and 2, in the developing
rat brain (50). Cross-linking identified the molecular weights of the factors as
approximately 110 and 115 kDa. However, these factors are not related to the
NF-B1 and or NF-B2 factors. Immunohistochemical evidence (51) suggests
that both NF-B p50 and RelA are constitutively active in some neurons of the
embryonic rat. This latter work also identified nuclear NF-B by gel mobil-
ity shift assay. Furthermore, B-dependent gene expression could be detected
in neuronal cell cultures. Experimentation has revealed that vascular adhesion
molecule-1 (VCAM-1) is expressed in the developing central nervous system on
neuroepithelial cells (52), which are precursors of glial cells and neurons. Uti-
lization of P19 embryonic carcinoma cells as a model of neural differentiation
revealed that expression of VCAM-1 correlated with induction of nuclear p50-
RelA dimers. NF-B activity in the brain may be involved with expression of
HIV in the central nervous system and may participate in normal brain function.
4.2 Transcriptional Regulation by NF-B Subunits
Consistent with their roles as transcription factors, c-Rel, RelB, and RelA con-
tain transcriptional activation domains (53, 54, and see 55). Additionally,
both c-Rel and RelA interact with the TATA-binding protein (TBP), and the
C-terminus of RelA interacts with the basal factor TFIIB (56 and references
therein). Studies in vivo and in vitro indicate that different NF-B dimers
have different transcriptional activation properties (57, 58). Strong evidence
indicates that interactions between NF-B and other transcription factors in-
fluence the ability of NF-B to regulate gene expression in a selective man-
ner. As described below, interactions between NF-B proteins, HMG-I(Y),
IRF-1, and bZIP proteins regulate inducible expression of the interferon 
gene. Interactions between NF-B proteins and bZIP proteins are implicated
in the inducible regulation of the genes encoding IL-8, E-selectin, and G-CSF,
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for example (see below). A complex that binds to enhancer A in the class I MHC
promoter and that is modulated by interferon γ or glucocorticoids reportedly
contains the p50 NF-B subunit in association with the bZIP protein fra-2 (59).
Additionally, a DNA-binding complex containing C/EBP and NF-B proteins
has been identified in avian lymphoid cells (60). An interaction between the
NF-B subunit RelA and the zinc finger protein Sp1 has been identified and
appears to regulate transcription directed by the HIV-1 LTR (61). The func-
tional outcome of transcriptional induction based on some of these interactions
likely involves cooperative DNA binding as well as transcriptional synergy.
4.3 Genes Regulated by NF-B
Extensive research has established a clear role for NF-B in the inducible regu-
lation of a wide variety of genes involved in immune function and inflammation
responses (for example, GM-CSF, IL-6, IL-8, IL-2, IL-2R, etc). An exten-
sive list of genes regulated by NF-B is provided in previous reviews (4, 5).
Following is a discussion of several of these.
The group of genes encoding cell adhesion molecules has been studied exten-
sively for an involvement of NF-B in their regulation. Vascular cell adhesion
molecule-1 (VCAM-1) is a cell surface protein typically found on endothelial
cells following exposure to TNF, IL-1, or LPS. VCAM-1 is a member of the im-
munoglobulin superfamily and binds circulating monocytes and lymphocytes
expressing 41 or 47 integrins and likely participates in the recruitment of
these cells to sites of tissue injury. VCAM-1 is also implicated in other cellular
processes because it is expressed in the developing central nervous system, in
human lymph nodes, and on bone marrow stromal cells. The promoter of the
VCAM-1 gene contains two essential NF-B sites (62), which are not sufficient
for activation, and may require an IRF-1 site that is located 30 to the TATA box
(63). Interestingly, IRF-1 was found to be inducible by cytokine treatment.
Furthermore, IRF-1 physically interacts with NF-B subunits, and its binding
is stimulated by binding of NF-B and HMG-I(Y). The functional requirement
for IRF-1 may explain the cell-type specificity of the VCAM-1 promoter. IRF-1
and NF-B may be important in the cytokine-induced regulation of multiple
promoters. Other genes encoding cell adhesion molecules, such as E-selectin,
ICAM-1, and MAd-CAM-1, are also regulated by NF-B (64–67). Expression
of E-selectin requires NF-B, the bZIP protein ATF-2, and HMG-I(Y) (64, 65).
Additionally, interactions between HMG-I(Y), NF-B, and an ets-like protein
(Elf-1) reportedly regulate expression of the IL-2 receptor  gene (68).
Regulation of the interferon  gene has been intensively studied by Maniatis
and colleagues (69, 70). The human gene is induced by viral infection of cells or
treatment with double-stranded RNA. One of the regulatory sites (GGGAAA-
TTCC; PRDII) in the IFN promoter interacts with both NF-B and the high
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mobility group protein HMG I(Y). HMG I(Y) stimulates the binding of NF-B
to PRDII by binding to the A/T-rich core sequence. Mutations that block either
NF-B or HMG I(Y) binding significantly block activation. These workers
propose a model in which interactions between bZip proteins (ATF-2 and c-Jun),
IRF-1, HMG I(Y), and NF-B form a higher order complex, which is required
for full activation of the IFN promoter (70). Thus a precise arrangement
of binding sites and a B site that interacts with HMG-I(Y) are required for
the proper transcriptional induction of the IFN gene. Strong similarities exist
between the inducible regulation of the IFN gene and those encoding adhesion
molecules (64).
Other genes regulated by NF-B that encode proteins playing important
roles in immune response and inflammation are the genes encoding the peptide
transporter TAP1 and the proteasome subunit LMP2 (71) as well as the MHC
class II invariant chain gene (72). Additionally, genes encoding tissue factor
(15, 73), inducible nitric oxide synthase (iNOS), and various cytokines are
regulated by NFB. iNOS catalyzes the high output of NO, and the iNOS
gene is transcriptionally activated in response to LPS and interferon gamma.
The inducible activation of NF-B stimulates the transcription of the iNOS
gene (74), leading to an increase in NO production. As discussed below, the
production of NO may feed back to inhibit NF-B activation. NF-B is strongly
implicated in the transcriptional regulation of several cytokine and growth factor
genes, including IL-2, IL-6, IL-8, and G-CSF. IL-2 contains an NF-B site that
has been studied by several groups (7). Activators of T cells such as PMA and
ionomycin activate NF-B and its binding to this site. The immunosuppressant
cyclosporin A blocks the activation of NF-B in response to T cell receptor–
mediated signals (75). Signaling through CD28, a costimulatory receptor, also
leads to the activation and binding of NF-B/Rel forms to a recently described
CD28 response element (CD28RE) in the IL-2 promoter (76). The CD28RE
is found upstream of other genes such as IL-3. Furthermore, expression of the
IL-8 gene is regulated by NF-B (77) and uses the CD28 costimulatory pathway
in T cells (78). G-CSF is a growth factor for hematopoietic cells produced
by mesenchymal and myeloid cells in response to activation by inflammatory
stimuli. A cooperative interaction between C/EBP (NF-IL6) and the RelA
subunit of NF-B is important in the regulation of G-CSF in response to TNF
treatment (79).
Although NF-B/Rel proteins are strongly implicated in the regulation of
genes involved in the immune system and in inflammation, these transcription
factors also regulate genes involved in control of cell growth. Two NF-B sites
have been identified in the c-myc promoter/enhancer region (80). The induction
of c-myc gene expression either by IL-1 or by the HTLV-I tax protein functions
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through the two NF-B sites. As discussed previously, classical NF-B or p65
homodimers appear to be the best activators of c-myc as Rel is only a weak
activator. NF-B binding proteins are also implicated in expression of the
translocated c-myc allele in Burkitt’s lymphoma (81) and in the transcriptional
regulation of the p53 gene (82).
4.4 Roles for NF-B Subunits Revealed in Gene
Knockout Studies
Knockout of most of the genes encoding NF-B/Rel subunits and two of the IB
forms has been recently accomplished. The studies confirm the importance of
NF-B/Rel proteins in immune function and have revealed several unexpected
findings.
4.4.1 NF-B1 Mice lacking the p50/p105 (NF-B1) subunits develop normally
but exhibit defects in immune responses involving B cells (83). In these mice,
the ability of B cells to proliferate in response to LPS is defective, and the
production of antibodies is impaired. Total serum Ig was approximately four-
fold lower in the knockout mice, and IgE was reduced approximately 40-fold.
This suggests that p50 plays an important role in heavy-chain class switch-
ing. Interestingly, p50 is reportedly (84) a critical factor for an IL-4-responsive
region in the Ig heavy-chain germline  promoter, responsible for switching
to IgE. NF-B1 −=− mice cannot effectively clear the pathogens Listeria or
Streptococcus and exhibit increased resistance to infection by EMC virus (83).
This resistance was correlated with increased expression of IFN, an important
antiviral protein. Thus p50 homodimers likely negatively regulate expression
of the IFN gene.
4.4.2 RELB Like the NF-B1 knockout mice, the RelB knockout mice do
not show a developmental phenotype but do show defects in normal immune
function and in hematopoiesis (85, 86). It had previously been speculated
that RelB plays an important role in the constitutive type expression of B-
regulated genes in lymphoid cells. RelB is expressed in the spleen, thymus,
lymph nodes, and intestine. In the thymus, RelB transcripts are concentrated in
the medulla with high levels of RelB in the nucleus of interdigitating dendritic
cells. The RelB−=−mice exhibited multifocal and mixed infiltration of inflam-
matory cells in several tissues. Additionally, the mice exhibited splenomegaly,
reduced antigen-presenting dendritic cells in the thymus, myeloid hyperpla-
sia, and impaired cellular immunity. These studies demonstrate an important
role for RelB in immune function and in the differentiation of dendritic cells
and thymic medullary epithelial cells. Furthermore, the data show that the
loss of RelB cannot be complemented by another member of the NF-B/Rel
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family and, therefore, that there is no simple redundancy within the NF-B/Rel
proteins. It will be important to identify the relevant genes regulated by RelB
that contribute to these immunological functions.
4.4.3 RELA The RelA (p65) null mice exhibit a dramatic phenotype–embry-
onic lethality apparently due to widespread apoptosis within the liver (87).
Day-14 embryos exhibit a normal liver phenotype, but by day 16 the liver
(specificially hepatocytes) has undergone extensive apoptosis. This phenotype
is similar to that observed with the c-Jun knockout and suggests that NF-B and
Jun may serve similar functions in development of the liver (see 87). The normal
induction of the p50-RelA heterodimer by TNF was lost in the RelA null mice
as was the inducibility of NF-B-regulated genes such as IB and GM-CSF.
4.4.4 c-REL The c-Rel knockout mouse develops normally, and cells from
all hemopoietic lineages are normal; however, mature B and T cells are not
responsive to certain mitogenic stimuli (88). The c-Rel −=− animals exhibit
normal Ig levels on splenic B cells and normal IL-2R chain on thymic T cells;
thus, c-Rel is not required for expression of these genes containing B binding
sites. Proliferation of B cells induced by LPS, CD40, or anti-IgM was defec-
tive for unknown reasons. A defective T cell–proliferative response induced
by engagement of the T cell receptor was observed, and CD28 costimulation
did not overcome this defect. Interestingly, proliferation of cells induced by
PMA and ionomycin was near normal. The inability of c-Rel −=− T cells to
respond to anti-TCR stimuli and CD28 costimulation was correlated with loss
of production of IL-2. Indeed, this proliferative block could be overcome by
the addition of exogenous IL-2. Thus, it appears that c-Rel is required for the
CD28 responsive element to be functional (see discussion above). Addition-
ally, the c-Rel deficient mice displayed deficient immunoglobulin production
in unchallenged animals, and T cell–dependent humoral immune responses to
antigenic challenge were also impaired.
4.4.5 IB AND BCL-3 IB null mice are apparently normal at birth but then
enter a wasting phase and die approximately 7 days after birth (89). The runted
mice have small spleens and thymuses, enhanced granulopoiesis, and scaly
skin. NF-B is constitutively activated in splenocytes and thymocytes as well
as in other cells. Upregulation of some genes expected to be regulated by NF-
B (G-CSF and VCAM-1) is detected. The loss of IB leads to the nuclear
localization of NF-B in most cell types, most prominently in the spleen and
thymus. This latter result suggests that IB is the dominant IB in these
organs. Treatment of IB −=− embryonic fibroblasts with TNF leads to ac-
tivation of NF-B through targeted degradation of IB, showing that at least
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in some cell types this inhibitor can be targeted by TNF. Furthermore, nuclear
NF-B levels remained elevated longer in −=− animals following treatment
with TNF, demonstrating a role for IB in controlling the postinduction re-
pression of NF-B. Clearly, the IB knockout studies will be informative in
understanding potential differential roles for the two major IB forms. Evi-
dence for a role in constitutive activation of NF-B in the phenotype of the
IB −=−mice is the observation that a cross between these mice and the p50
−=− mice extends the life expectancy of the former (89).
The Bcl-3 gene knockout has been derived very recently. So far, no obvious
developmental or immunological abnormalities have appeared in the mice (A
Berns, I Verma, personal communication).
5. MECHANISMS FOR THE ACTIVATION AND
CONTROL OF NF-B ACTIVITY
Enormous progress has been made toward identifying the mechanisms whereby
NF-B is activated to move into the nucleus in response to numerous stimuli.
Specific molecular events involved in this activation are now well described
and offer insights into a fascinating control mechanism. Despite this progress,
many important questions remain regarding the pathways and mechanisms of
NF-B activation.
5.1 Phosphorylation of IB Is Coupled To Its Proteolysis via
the Ubiquitin Pathway
In vivo analysis has shown that inducer-mediated activation of NF-B is cor-
related with the hyperphosphorylation of IB and its subsequent degradation
(reviewed in 4–12). Paralleling the loss of IB in the cytoplasm is the ap-
pearance of NF-B in the nucleus. Reagents such as antioxidants or certain
protease inhibitors that inhibit phosphorylation block the appearance of nuclear
NF-B. Based on studies showing that IB is intrinsically unstable when not
associated with NF-B, phosphorylation of IB was generally thought to
lead to its dissociation from NF-B, which resulted in proteolysis (9). Recent
experiments have offered a different interpretation.
One set of experiments (90–96) showed that hyperphosphorylated IB
could be coimmunoprecipitated with NF-B, suggesting that inducible phos-
phorylation does not cause the dissociation of IB from NF-B. Second,
experiments with a class of protease inhibitors called peptide aldehydes demon-
strated that these compounds block the degradation of IB and the nuclear
appearance of NF-B, but do not block inducible phosphorylation of IB
(90–97). In addition, these studies led to the important proposal that a target
of peptide aldehydes, the proteasome, is responsible for the signal-mediated
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degradation of IB (97). Like IB, IB is targeted for degradation in re-
sponse to the inducers LPS and IL-1. Evidence that IB is degraded by the
proteasome is provided by data that show that peptide aldehydes specific for
the proteasome block its degradation (T Finco, J Reuther, A Beg, D Ballard, S
Shenolikar, A Baldwin, submitted).
What mechanism targets IB, and presumably IB, for degradation? Ev-
idence that phosphorylation precedes degradation (95) suggests that phospho-
rylation of IB is required for degradation. Mutation of two serines near the
N-terminus of IB, ser32 and ser36, blocked inducible phosphorylation and
also blocked degradation (98–100). Phosphopeptide mapping demonstrates
that these two serines are inducibly phosphorylated in response to various ac-
tivators of NF-B (J DiDonato, M Karin, personal communication). Recent
work indicates that IB is ubiquitinated in response to inducer, and mutation of
ser32 and ser36 inhibits the inducible ubiquitination (101). Importantly, ubiq-
uitinated IB is degraded by purified preparations of proteasomes. Mutation
of two lysine residues in the N-terminus block ubiquitination and degradation
of IB but not induced phosphorylation (102). Presumably these two lysines
are the targets for uibiquitination. Thus the current model is that targeted phos-
phorylation of IB leads to the ubiquitination of this protein, which leads to
degradation by the proteasome (see Figure 3). A question raised by these data
is, what makes the phosphorylated form of IB a substrate for the ubiquitina-
tion pathway? Possibly the lysine residues to be ubiquitinated are masked by
secondary or tertiary structure until the nearby serines are phosphorylated.
Although inducible phosphorylation of IB (and presumably IB) plays
a critical role in the activation of NF-B, IB is also constitutively phospho-
rylated. Recent evidence suggests that casein kinase II (CKII) can associate
with and phosphorylate the C-terminal region of IB (103; J Hiscott, personal
communication). Interestingly, deletion of the C-terminus inhibits degradation
(but not association with NF-B) (98, 104, 105) and also abrogates the ability
of IB to inhibit DNA binding by NF-B (20). Thus, constitutive phospho-
rylation of IB in the C-terminal region may be required for degradation,
possibly mediated by the PEST residues found in this domain. Additional roles
for constitutive phosphorylation of IBmay include regulation of the stability
of free IB or assembly with NF-B subunits.
5.2 NF-B Subunits Are Targeted for Inducible
Phosphorylation
Both the NF-B1 (p105) and NF-B2 (p100) proteins are cytoplasmic and are
associated with different NF-B/Rel proteins. As discussed above, this associ-
ation may be as dimers or, as recently proposed, trimers. Several of the NF-B
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Figure 3 Generalized NF-B activation scheme. Following exposure of a cell to inducer, IB
(either IB, IB or one of the precursor proteins) becomes phosphorylated (step 1) by a presently
unknown kinase(s). (Note that IB exhibits a basal level of phosphorylation.) The IB form then
becomes ubiquitinated (step 2) and degraded by the proteasome (step 3). In the case of p105, the
degradation is partial (generating p50). NF-B then translocates to the nucleus where it activates
a variety of genes (step 4) including IB and p50/p105. See text for details.
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inducers lead to the degradation of the p105 precursor protein with the appear-
ance of the p50 form (4, 5). This degradation is limited to the C-terminal half
of the protein (97). As with IB targeting, degradation appears to be preceded
by inducible phosphorylation (106, 107) and is mediated by ubiquitination and
processing by the proteasome (see Figure 3; 97). Degradative processing of
p105 that is in association with other NF-B subunits (for example, RelA) may
lead to nuclear translocation directly or to association with an IB form (see
Figure 3).
Reagents that induce NF-B activation via the inducible phosphorylation of
IB reportedly also lead to the inducible phosphorylation of subunits other than
those for the precursor/IB-like forms. For example, the RelA subunit becomes
rapidly phosphorylated in response to TNF (108; D Wang, T Finco, A Baldwin,
unpublished). A role for this inducible phosphorylation has been suggested to
involve enhancement of DNA binding (106) but may also be correlated with
release from IB, nuclear translocation, activation of transcription functions,
or for differential targeting of NF-B forms that may be associated with IB
or IB (see below).
5.3 Mutual Regulation of NF-B and IB
Initial studies that demonstrated the correlation of IB loss with the appear-
ance of nuclear NF-B also indicated that IB levels recovered within an
hour or so (see 4, 5 for reviews). This reappearance of IB depended on
protein synthesis and correlated with the inducible expression of IB mRNA.
Furthermore, transfection into cells of an expression vector for RelA led to
an increase in IB mRNA. It was therefore proposed that nuclear NF-B
caused the transcriptional activation of the IB gene. Promoter analysis has
confirmed that the IB gene contains multiple NF-B binding sites and that
these sites are functional in the upregulation of gene expression in response to
inducers that activate NF-B (see 4, 5). Evidence has been presented, however,
that adherent monocytes (from which IB was initially cloned) upregulate
IB mRNA through a nontranscriptional event (109). These results indicate
that NF-B and IB are components of a mutual regulatory system in which
the levels of one regulatory component control the activity or quantity of the
other.
The rapid reaccumulation of IB following its loss is apparently important
in reestablishing cytoplasmic pools of NF-B/IB complexes. Additionally,
this reaccumulation appears to repress NF-B activity following induction be-
cause resynthesized IB enters the nucleus, interacts with NF-B forms, and
inhibits DNA binding (110). Consistent with this model is the observation that
IB −=− cells exhibit high nuclear levels of NF-B for long times follow-
ing induction with TNF (89). A mechanism for removal of NF-B from the
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nucleus is suggested by the presence of a potential nuclear export sequence
in IB (111). Thus IB, and not IB (see below), is considered to be
important for the postinduction repression of NF-B.
5.4 Similarities and Differences Between IB- and
IB-Controlled Pathways
As discussed previously, many similarities exist between IB and IB. Ev-
idence indicates, however, that IB does not respond to treatment with TNF
or PMA but does respond to LPS or IL-1 in pre-B or Jurkat T cells (26). In ad-
dition, IB reportedly does not reaccumulate following induction of NF-B;
thus a persistent activation of NF-B follows. Mechanisms that would pre-
vent IB, which rapidly reaccumulates following induction, from inhibiting
the IB-released NF-B have been proposed. One idea is that NF-B that
is associated with IB would be modified (possibly by phosphorylation) so
that it could not be targeted for inhibition by IB. Many issues remain to
be clarified regarding differences between IB and IB. One question is
whether different kinases function to target the two forms of IB. Evidence for
this is that IB is targeted for degradation with slower kinetics than IB and
that there is apparent inducer specificity in the targeting of the two IB forms.
However, recent evidence (J DiDonato, M Karin, personal communication)
indicates that serines in the N-terminus of IB, in homologous positions to
ser32 and ser36 in IB, play critical roles in the targeted degradation of this
protein. This would indicate that a kinase that is identical or very similar to the
IB kinase would target IB. Additionally, it is not clear whether targeting
of IB occurs in all cell types (see discussion above relevant to the IB gene
knockout).
5.5 Tangled Evidence for the Signal Transduction Pathways
5.5.1 KINASES AND PHOSPHATASES Much research is now directed at elucidat-
ing the signal transduction pathways involved in controlling activation of NF-
B. It is clear that the many different inducers initiate their pathways through
distinct receptors. How these different responses converge on IB is still un-
known. Mutations of ser 32 and 36 inhibit activation of NF-B controlled by
T cell activation signals PMA, TNF, LPS, HTLV-I tax, and okadaic acid. Thus,
a single kinase activated by multiple pathways may target these residues in
NF-B.
Nevertheless, several kinases have been implicated in the activation of NF-
B. The best data exist for the double-stranded RNA activated kinase (PKR),
which phosphorylates IB in vitro (112). Furthermore, in vivo inactivation
of this kinase inhibits the ability of double-stranded RNA to activate NF-B
(113). However, this inactivation did not block activation of NF-B by TNF
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and presumably other inducers. It would be interesting to map the potential
phosphorylation sites on IB targeted by dsRNA-activated kinase. Another
kinase, Raf-1, has been proposed, to target IB (114). Evidence for an in-
volvement of Raf in the activation of gene expression directed through a B
site has been presented through the utilization of constitutively active and dom-
inant negative vectors (115). Activation of Ras or Raf may not lead to the
nuclear translocation of NF-B, but it can activate gene expression through
a B site. The mechanism is unclear but may involve the stimulation of the
transcriptional activation domains of constitutively nuclear forms of NF-B (T
Finco, A Baldwin, unpublished). Dominant negative experiments as well as
direct expression experiments have implicated PKC as a regulator of NF-B
activation (116). Due to their activation by inducers of NF-B such as inflam-
matory cytokines, UV, and LPS, there has been speculation that members of
the stress-activated protein kinases (SAPKs) or their regulators may play a role
in IB phosphorylation, but no published data exist regarding this possibility.
Additionally, a kinase reportedly associated with NF-B/IB complexes also
appears to phosphorylate the NF-B subunits (117).
Phosphatases likely play an important role in the activation of NF-B, either
regulating kinase pathways that may control the signal transduction pathway or
by directly dephosphorylating IB. Based on inhibition by cyclosporin A and on
transfection studies, the Ca2C-dependent phosphatase calcineurin is apparently
involved in the activation of NF-B in T cells (75). In addition, FK506, an
inhibitor of calcineurin, blocks the activation of c-Rel in B and T cells (118).
The target for calcineurin in this pathway is not known. Inhibitors of the ser/thr
phosphatases PP1 and PP2A, such as okadaic acid, potently activate NF-B,
suggesting the involvement of a phosphatase in regulating some aspect of the
pathway. Evidence that PP2A can directly dephosphorylate IB has been
provided (T Finco, J Reuther, A Beg, D Ballard, S Shenolikar, A Baldwin,
submitted; 119).
5.5.2 CERAMIDE, REACTIVE OXYGEN INTERMEDIATES, AND REDOX STATE Sec-
ond messengers may be involved in the early activation pathway of NF-B. The
generation of ceramide in response to TNF or IL-1 may be critical in initiating
the events leading to NF-B activation via degradation of IB (see 120 and
references therein). According to the current model, the interaction of TNF with
the 55-kDa TNF receptor activates an acidic sphingomyelinase (Smase) through
the generation of diacylglycerol by a phosphatidylcholine-specific phospholi-
pase C. Smase leads to the production of ceramide. That addition of ceramide
or sphingomyelinase to cells leads to the activation of NF-B (see 120) supports
this model. Recent evidence indicates that addition of acidic SMase to a cell-free
system leads to the degradation of IB (121). Based on these data, it has been
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proposed that the generation of ceramide leads to the activation of a kinase that
phosphorylates IB. There is also evidence against a role for ceramide in the
activation of NF-B. Cells deficient in acidic SMase can activate NF-B in re-
sponse to TNF or IL-1 (122). Possibly another SMase is involved in the process
of activation of ceramide in these cells. Second, inhibition of the ceramide path-
way by chronic stimulation of cells with PMA does not inhibit the ability of TNF
to activate NF-B (123). Finally, levels of ceramide that activate the Jun kinase
(JNK) are not sufficient to activate NF-B (124). Clearly more experimentation
is needed to resolve whether ceramide is an initiator of NF-B activation, and,
if so, what regulatory pathways exist downstream of this molecule.
Reactive oxygen intermediates (ROIs) have also been proposed to be involved
in the activation of NF-B (4). This is based on the observations that treatment
of some cells with H2O2 can activate NF-B and that certain antioxidants such
as N-acetyl cysteine or PDTC can block activation of NF-B by blocking the
signal-induced phosphorylation of IB. Additionally, many of the known
inducers of NF-B lead to the generation of ROIs. Compelling arguments for
the role of ROIs in the activation of NF-B have been presented by Baeuerle
and colleagues (4, 125). These authors propose that the initial response to
TNF and other inducers is the production of superoxide anion followed by the
generation of H2O2 (125). Identification of signaling components that may
function downstream of H2O2 in the potential activation of NF-B is lacking.
Arguments against ROI involvement in NF-B activation have been published
recently (126, 127) .
Activation of NF-B binding by thioredoxin, a protein involved in main-
taining the redox environment of the cell, involves the reduction of a disulfide
bond at cys62 of the p50 subunit (see 128). The sequence of this region is
conserved in many of the NF-B/Rel family proteins. Recently, the structure
of thioredoxin and a peptide encompassing the cys62 region has been reported
(128). This part of p50 is found in the L1 loop and makes apparently critical
contacts with the B DNA binding site. Expression of thioredoxin increases
following exposure of cells to UV light or to H2O2 (129), suggesting a possible
role in increasing NF-B activity in response to these inducers.
5.6 Hypoxia Appears To Activate NF-B via a Unique Pathway
Exposure of cells to low oxygen concentrations results in the activation of
NF-B (130), which is likely to be important in situations such as angiogenesis
associated with tumorigenesis, and in ischemia. Not surprisingly, activation of
NF-B by hypoxia is correlated with the loss of IB. However, an unexpected
result was that IB is apparently tyrosine phosphorylated in hypoxic cells
(130). This would indicate that a kinase is involved in the phosphorylation
of IB that is distinct from that utilized in responses to TNF, IL-1, LPS, or
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PMA. Interestingly, it has been proposed that Ras and Raf, but not Map, kinases
are involved in this activation (131). These results need to be followed up, the
phosphorylation site(s) mapped, and the functional consequence of the reported
tyrosine phosphorylation tested.
5.7 Activation of NF-B by Viral Proteins
Many viral gene products activate NF-B. This may be advantageous to the
virus for several reasons. First, several viruses (such as HIV, CMV, and SV40)
have NF-B binding sites in their promoter/enhancer regions. Second, NF-B
appears to regulate genes required for viral replication. For example, a factor
required for the HIV Rev splicing function may be regulated by NF-B (132).
Finally, activation of NF-B may provide a favorable environment for viral
replication, possibly by serving as a mitogenic regulator.
Probably the most intensively studied viral protein known to activate NF-B
is the Tax protein of HTLV-I. Tax has been proposed to activate NF-B by
different mechanisms. One mechanism appears to be through a direct physical
interaction with the NF-B2 100-kDa protein (24, 133, 134). Second, evidence
has been provided that Tax activates a signal transduction pathway leading
to phosphorylation and degradation of IB and to the nuclear appearance of
NF-B (90, 135, 136). Finally, Tax may directly interact with NF-B subunits
bound to their target sites and stimulate transcription (137). Activation of NF-
B by Tax is likely to play an important role in the pathogenesis of HTLV-I,
possibly through the upregulation of genes encoding IL-2, IL-2R, and IL-6
(138). It has been proposed that the HIV Tat protein activates NF-B (139).
Other evidence indicates that Tat potentiates NF-B activation by TNF by
altering the cellular redox state (140). Recent evidence suggests that the B
sites in the HIV LTR are absolutely required for induction of LTR-reporter gene
activity in peripheral CD4C T cells in response to Tat (141). Another important
HIV protein, nef, can activate NF-B when functioning as a cell membrane–
associated protein or can inhibit its activation if expressed cytoplasmically
(142, 143). A transforming protein of Epstein-Barr virus, the latent membrane
protein (LMP-1), has been shown to activates NFB (144–147). A mechanism
for activation may be that LMP-1 associates with factors that are liklely involved
with signaling directed by the TNF receptor (148).
5.7.1 CONCLUSION It is unlikely that significant progress will be made on
the NF-B signaling pathway(s) until research proceeds directly downstream
from known receptors and directly upstream from the final phosphorylated
substrates (IB and NF-B subunits). For example, progress in this regard
has been made through the identification of a protein associated with the TNF
receptor that functions in the signaling of NF-B activation (149). This protein,
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TRADD, interacts with the intracellular domain of the 55-kDa TNF receptor
(TNF receptor 1). Overexpression of TRADD leads both to apoptosis and to the
activation of NF-B. However, the pathways for activation of NF-B and for
apoptosis appear to be distinct since crmA, an inhibitor of the IL-1-converting
enzyme, blocked apoptosis but not the activation of NF-B. At the other end
of the pathway, the kinase(s) involved in the phosphorylation of IB and of
NF-B subunits must be identified. Such data will permit definitive dissection
of the signaling pathways involved in NF-B activation.
5.8 Inhibitors of NF-B Activation
Studies utilizing compounds that inhibit NF-B activation may provide insight
into the activation pathways, may clarify biological situations where inhibi-
tion of NF-B is functionally important, and suggest therapies for diseases
related to the acute or chronic activation of NF-B. An example is tepoxalin,
a dual inhibitor of cyclooxygenase and 5-lipoxygenease, which functions to
inhibit NF-B induction by several inducers in multiple cell types (150). Other
examples are discussed below.
5.8.1 IL-10 Interleukin-10 (IL-10) inhibits the transcription of a variety of
cytokine genes associated with TH1 T cell responses. Recently, IL-10 was
shown to inhibit the induction of NF-B by LPS in human peripheral blood
mononuclear cells (151). These data provide an important link in understanding
the inhibitory functions of IL-10 toward certain cytokines. It is intriguing to
speculate that the mucosal inflammation with abnormal TH1 T cell responses
seen in IL-10-null mice (152) is due in part to an inability to block the function
of NF-B.
5.8.2 GLUCOCORTICOIDS, SALICYLATES, AND OTHER IMMUNOSUPPRESSANTS
Glucocorticoids are widely used immunosuppressants. For example, pred-
nisone is used to suppress immune responses in organ or bone marrow trans-
plants, and is also used in chronic inflammatory diseases such as arthritis.
Glucocorticoids reportedly inhibit NF-B by two mechanisms. First, several
groups report that activated glucocorticoid receptors directly interact with and
inhibit activated NF-B subunits (153–156). A second mechanism involves
the transcriptional activation of the IB gene in response to treatment with
glucocorticoids (157, 158). Glucocorticoids, by upregulating IB protein
levels, function to block nuclear translocation of NF-B and DNA-binding.
Salicylates (159), which are nonsteroidal anti-inflammatory drugs, inhibit the
activation of NF-B at concentrations used to treat arthritis.
Cyclosporin A (CsA) and rapamycin, both important immunosuppressants
that target T cells, inhibit the activation of NF-B induced in T cells by different
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stimuli. CsA blocks the activation of NF-B in response to the engagement
of the T cell receptor (75). One group has reported that rapamycin blocks the
induction of NF-B following CD28 costimulation in T cells (160). Interest-
ingly, this study showed that CD28 signaling caused a sustained inactivation of
IB. FK506, another inhibitor of calcineurin, blocked the activation of c-Rel
in both B and T cells (118).
5.8.3 NITRIC OXIDE Two recent reports indicate that production of nitric oxi-
de (NO) inhibits the activation of NF-B in endothelial cells (161, 162). The
rationale for such a study is that NO inhibits platelet adhesion and smooth
muscle proliferation, and modulates leukocyte adhesion to the endothelium.
Thus, the production of NO suppresses immune and inflammatory responses.
NO inhibits the activation of NF-B in response to treatment with TNF (161).
The second study showed that NO inhibits the activation of NF-B and provided
evidence that this is through the activation of IB (162). Thus NO appears
to inhibit activation of NF-B through a mechanism similar to that described
for glucocorticoids (i.e. through the upregulation of IB). Since NF-B
transcriptionally regulates the iNOS gene, production of NO may feed back
to block its own production through the inhibition of NF-B. Adding to the
complexity, production of NO in lymphocytes reportedly leads to the activation
of NF-B (163).
5.8.4 cAMP As with glucocorticoids and other immunosuppressants, agonists
that elevate cAMP inhibit IL-2 expression. This appears to occur through the
inhibition of two factors that activate the transcription of IL-2 (164). One of
these is NF-B and the other is uncharacterized and is called the “TGGGC”
factor. The inhibition of NF-B may involve decreased synthesis of NF-B sub-
units, and decreased degradation or upregulation of IB (164, 165). Agonists
that increase cellular cAMP levels may be important modulators of immune
responses. Prostaglandin E2, an activator of cAMP, may modulate immune
function by inhibiting IL-2 secretion on the one hand and activating IL-4 and
IL-5 on the other. Thus activators of cAMP may play an important role in the
differentiation of TH cells into either the TH1 or TH2 category (164, 165).
6. NF-B AND DISEASE
Because of its direct role in regulating responses to inflammatory cytokines
and endotoxin, the activation of NF-B may play a role in the development of
chronic diseases such as rheumatoid arthritis or in acute situations such as septic
shock. Support for a critical role for NF-B activation in arthritis comes from
two observations: NF-B is activated in the arthritic synovium (S Makarov, A
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Baldwin, unpublished), and therapies that are used for treatment, such as pred-
nisone (see above) and gold compounds (166), are now known to block NF-B.
Septic shock is a systemic inflammatory response that develops when LPS
or other microbial products stimulate expression of various inflammatory cy-
tokines. The massive production of these proteins ultimately leads to reduction
in blood pressure and to general organ failure. It has recently been proposed
that the production of nitric oxide in response to LPS regulates important as-
pects of septic shock (see 167). These experiments showed that iNOS-deficient
mice were protected from septic shock. Since NF-B activates transcription of
the iNOS gene (see above), activation of NF-B by LPS may play a role in the
development of septic shock. Other activators of NF-B, such as TNF, may
also mediate septic shock (see 168). Autoimmune diseases such as systemic
lupus erythromatus (SLE) may involve activation of NF-B as well (W Jarjour,
personal communication). Additionally, Alzheimer’s disease may also involve
activation of NF-B in a chronic setting, since the amyloid  peptide causes
production of ROIs and activates gene expression through B sites (169). As
described previously, NF-B plays an important role in the activation of HIV
gene expression. The influenza virus protein hemagluttinin activates NF-B,
and this activation may contribute to viral induction of cytokines and to some
of the symptoms associated with flu (170). Other examples involving NF-B
and disease pathogenesis are briefly discussed below.
6.1 Atherosclerosis
Initiation and progression of atherosclerosis is related to the oxidation of lipids
in LDLs. These oxidized lipids become trapped in the extracellular matrix of the
subendothelial space and apparently activate NF-B, leading to transcriptional
activation of genes involved in the inflammatory process (171). This process
leads to the development of the fatty streak associated with atherosclerosis.
Interestingly, mice that are susceptible to atherosclerosis exhibit activation of
NF-B when fed an atherogenic diet (172). Another important contributor
to atherosclerosis is thrombin, a serine protease that serves several important
roles in actions upon inflammatory cells as well as cells of blood vessel walls.
Thrombin likely contributes to the proliferation of the vascular wall that occurs
in atherosclerosis and restenosis. Thrombin stimulates the proliferation of
vascular smooth muscle cells through the activation of NF-B (173). Overall,
these data provide substantial evidence that NF-B activation is an important
contributor to events involved in atherosclerosis.
6.2 Oncogenesis
Evidence for involvement of NF-B or IB members in oncogenesis is based
on several observations (4, 5): (i) NF-B proteins are members of a proto-
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oncogene family; (ii) the NF-B2 gene and the Bcl-3 gene are translocated in
certain lymphomas; (iii) NF-B is activated in quiescent fibroblasts in response
to serum growth factors; (iv) NF-B is activated by viral transforming proteins
(Tax and LMP-1, for example; see above); and (v) exposure of cells to IB
antisense results in oncogenic transformation (174). Additionally, antisense to
RelA blocked tumorigenesis induced by Tax in vivo (175). Evidence for a role
of translocated NF-B2 in oncogenesis is based on observations that the normal
repressive function of p100 is lost when the ankyrin repeats are deleted in the
translocated allele (176, 177). A role for NF-B/Rel proteins in human cancer
presumably would involve transcriptional functions, such as the upregulation of
the c-myc gene (see above). Conversely, it has been proposed that the activation
of NF-B in macrophages by the antineoplastic agent taxol may contribute to
the compound’s antitumor properties (178).
6.3 Ataxia Telangiectasia
Ataxia telangiectasia (AT) is a human disease characterized by neurological,
radiobiological, and immunological deficiencies. Fibroblasts from AT patients
are extremely sensitive to ionizing radiation, exhibiting aberrant regulation of
DNA synthesis. Recently, a truncated form of IB (presumably functioning
as a “super-repressor” based on the loss of the critical N-terminal serines) was
shown to protect AT cells from killing by ionizing radiation and to correct the
defect in DNA synthesis (179). These AT cells express constitutive levels of an
NF-B-like activity. Expression of the truncated form of IB reduced NF-B
levels and blocked the radiobiological effects. The gene involved in AT was
recently cloned, and the encoded protein is related to yeast lipid kinases TOR1
and TOR2 as well as mammalian PI-3 kinase (180). An additional homology
exists with the yeast RAD3 protein, which is involved in cell cycle control. It is
proposed that the mutations in the AT gene render it nonfunctional. It is unclear
whether NF-B is activated in other cell types of AT patients and, if so, whether
NF-B may contribute to the neurological or immunological deficiencies. An
interesting connection exists between AT patients and the IB gene knockout
mice (89) in that both exhibit small spleens and thymuses. Thus, inappropriate
activation of NF-B in both cases could cause an immunological defect. The
mechanism that relates the loss of function of a PI-3-like kinase/Rad3-like
protein to activation of NF-B is presently unclear.
7. SUMMARY
Ten years of research on NF-B has led to a much greater understanding of
the role of this family of transcription factors and their inhibitors in immunity,
inflammation, and cell growth and development. The next challenge is to
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untangle the signal transduction pathways involved in controlling activity of
NF-B and to uncover new gene targets for these proteins in immunological
and nonimmunological function. Cell type–specific functions for NF-B, for
example in neurons, should be pursued. The functional roles of IB and
IB, as well as potential new forms of inhibitors, need to be clearly delineated.
Additionally, it will be important to understand the exact roles for NF-B in
regulating apoptosis in several situations. Clarification of the mechanisms
through which dysregulation of NF-B contributes to disease is clearly needed.
This could promote the development of specific inhibitors of NF-B and thereby
assist in treating certain of these diseases.
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